{"id":"dorzolamide-timolol-brimonidine-and-latanoprost","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation/hyperemia"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Allergic conjunctivitis"},{"rate":null,"effect":"Systemic beta-blocker effects (bradycardia, fatigue)"},{"rate":null,"effect":"Dry mouth"}]},"_chembl":{"chemblId":"CHEMBL2062257","moleculeType":"Small molecule","molecularWeight":"442.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dorzolamide inhibits carbonic anhydrase to decrease aqueous humor production. Timolol is a non-selective beta-blocker that reduces aqueous humor secretion. Brimonidine is an alpha-2 agonist that decreases aqueous humor production and increases uveoscleral outflow. Latanoprost is a prostaglandin F analog that increases uveoscleral outflow. Together, these four agents provide additive intraocular pressure reduction.","oneSentence":"This fixed-dose combination reduces intraocular pressure through four complementary mechanisms: carbonic anhydrase inhibition, beta-adrenergic blockade, alpha-2 adrenergic agonism, and prostaglandin F analog activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:35:27.195Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT06369077","phase":"PHASE4","title":"How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?","status":"TERMINATED","sponsor":"CT Glaucoma Associates","startDate":"2024-04-22","conditions":"Glaucoma, Open-Angle, Glaucoma; Drugs","enrollment":36},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT01887223","phase":"PHASE2","title":"Transconjunctival Needling Revision Versus Medical Treatment","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2010-05","conditions":"Primary Open Angle Glaucoma","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PRO-122","Krytantek Ofteno PF®","Gaap Ofteno PF®"],"phase":"marketed","status":"active","brandName":"Dorzolamide-timolol-brimonidine and latanoprost","genericName":"Dorzolamide-timolol-brimonidine and latanoprost","companyName":"Laboratorios Sophia S.A de C.V.","companyId":"laboratorios-sophia-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This fixed-dose combination reduces intraocular pressure through four complementary mechanisms: carbonic anhydrase inhibition, beta-adrenergic blockade, alpha-2 adrenergic agonism, and prostaglandin F analog activity. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}